Royalty Pharma
30.07
0.08 (0.27%)
At close: Jan 14, 2025, 3:59 PM
30.10
0.12%
After-hours Jan 14, 2025, 06:54 PM EST
undefined%
Bid 30.2
Market Cap 13.36B
Revenue (ttm) -
Net Income (ttm) -
EPS (ttm) 2.54
PE Ratio (ttm) 11.84
Forward PE n/a
Analyst Buy
Ask 30.75
Volume 5,024,206
Avg. Volume (20D) 3,017,040
Open 29.86
Previous Close 29.99
Day's Range 29.67 - 30.20
52-Week Range 24.05 - 31.66
Beta undefined

About RPRX

Royalty Pharma plc operates as a buyer of biopharmaceutical royalties and a funder of innovations in the biopharmaceutical industry in the United States. It is also involved in the identification, evaluation, and acquisition of royalties on various biopharmaceutical therapies. In addition, the company collaborates with innovators from academic institutions, research hospitals and not-for-profits, small and mid-cap biotechnology companies, and pha...

Industry Biotechnology
Sector Healthcare
IPO Date Jun 16, 2020
Employees 75
Stock Exchange NASDAQ
Ticker Symbol RPRX

Analyst Forecast

According to 6 analyst ratings, the average rating for RPRX stock is "Buy." The 12-month stock price forecast is $41, which is an increase of 36.37% from the latest price.

Buy 83.33%
Hold 16.67%
Sell 0.00%
Stock Forecasts

Next Earnings Release

Royalty Pharma is scheduled to release its earnings on Feb 13, 2025, before market opens.
Analysts project revenue of $688.68M, reflecting a 15.55% YoY growth and earnings per share of 1.07, making a -6.96% decrease YoY.
5 days ago · Source
+12.56%
Royalty Pharma shares are trading higher after the... Unlock content with Pro Subscription